Breyanzi (lisocabtagene maraleucel) is now approved for adults with relapsed or refractory follicular lymphoma who have received at least two other systemic therapies, according to a May 15 news release from BMS.
In a clinical trial of 101 patients, 94% of study participants achieved a complete response and 97% showed an overall response rate.
The one-time infusion therapy is also approved for relapsed or refractory large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, and small lymphocytic lymphoma.
